* We trim EBIT by 4-3% on slightly lower margins * Strong growth continues, with impressive margin r...
Rekord i både omsättning och vinst i säsongsmässigt starkt kvartal.
* We raise our long-term EBIT estimates on better growth * Short-term margins sacrificed, but LT gro...
Administer’s Q3 was soft, with lower net sales weighing on profitability.
Redeye considers Arise’s Q3 2025 report to be largely in line with estimates when adjusting for one-...
* Beat driven by strong paper performance * Challenging markets * Outlook remains muted Beat driven ...
Redeye’s analyst just published a Research Update on Devyser Diagnostics.
Redeye comments on Transtema’s Q3 report, showing 5.
Redeye provides an initial take on Kontigo Care’s Q3 2025 results.
Redeye provides an initial take following the release of Optomed’s Q3 2025 report.
Redeye provides its first take on Camurus’ Q3 report 2025, published this morning.
Redeye updates on NextCell following its Q4 report, which showed figures largely aligning with estim...
Redeye updates on G5 Entertainment following Q3 results, which were softer than expected due to high...
Redeye comments on Oncopeptides’ 3rd quarter report.
Redeye returns with smaller near-term forecast adjustments following a Q3'25 report that was largely...
* An NDA for Orviglance submitted to the FDA * Patience for a partner deal * Fair value range update...
* Q3 soft, lower volumes from two major customers * We cut '26e-'27e sales and EBIT by 6% and SEK 6m...
* Operational leverage supports beat on adj. EBITDA * Adj.
Redeye remains confident on the case as we see solid prospects for continued rapid growth and good o...
Redeye comments on the announcement that Moberg Pharma has signed an exclusive license agreement wit...
